A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia

Article ID	Journal	Published Year	Pages	File Type
8528308	Clinical Therapeutics	2017	14 Pages	PDF

Abstract

Triple combination therapy with amlodipine/losartan/rosuvastatin can be an effective therapeutic strategy in patients with hypertension combined with dyslipidemia. These findings will form the foundation of the future development of a single-pill triple combination. ClinicalTrials.gov identifier: NCT02899455.

Keywords

Hypertension Calcium channel blocker Angiotensin receptor blocker HMG-CoA reductase inhibitor Hypercholesterolemia

Related Topics

Health Sciences Medicine and Dentistry Medicine and Dentistry (General)

Preview

A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia

Authors

Hae-Young MD, Seok-Yeon MD, Kee-Joon MD, Byung-Su MD, Dong-Hun MD, Hae Ok MD, Dong-Ryeol MD, Joon Hyouk MD, Kwang Je MD, Tae Ho MD, Ju Hyeon MD, Sang Min MD, Ji-Yong MD, Kye Hun MD, Jaemin MD, Woo-Shik MD, Si-Wan MD, Dae-Gyun MD, Seung Woo MD,